In conclusion, BARI-STEP, a randomized, placebo-controlled trial investigating the use of once-weekly semaglutide 2.4 mg in a post-bariatric patient population with a suboptimal clinical response, demonstrates that semaglutide 2.4 mg in patients with a suboptimal clinical response results in substantial, clinically relevant body weight reduction, and improvements in metabolic health and quality of life
What that means practically: this is a peptide with a real clinical evidence base, a specific mechanism, a defined dosing protocol, and a narrow set of people its genuinely right for
Regular physical activity can also improve bowel function
ExcelMale forum members who have tracked labs while using GHK-Cu (both topical and injectable) have consistently reported no measurable change in serum DHT or estradiol
My first time was such a great experience and everyone was so welcoming and sweet